Associated Papers
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Innes AJ et al.
Leukemia, 2024
39300220 (PubMed )
Supplement: 41375_2024_2411_MOESM1_ESM.pdf
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia.
Korfi K et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2015
25712455 (PubMed )
Supplement: supp_mdv110_mdv110supp.docx
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Khorashad JS et al.
Blood, 2013
Select a paper to view details